Table 2 Clinical characteristics of the MGUS patients and their corresponding bolus and continuous infusion dosages of [¹³C₅]-glutamine

MGUS #1^c

52

F

0.4 g/dL

IgG lambda

5.21%

MGUS #2^a

65

M

NQ; IgA, 476 mg/dL

IgA kappa

4.78%

MGUS #3^c

71

M

1.2 g/dL

IgG lambda

4.61%

MGUS #4^c

66

M

0.7 g/dL

IgG kappa

5.57%

MGUS #5^b

69

M

1.4 g/dL

IgG lambda

3.49%

MGUS #6

48

M

1.2 g/dL

IgG kappa

4.90%

MGUS #7

56

F

1.2 g/dL

IgG kappa

5.84%

MGUS #8^c

61

F

NQ; IgG, 867 mg/dL

IgG lambda

6.31%

MGUS #9^c

71

M

NQ; kappa FLC, 47.5 mg/dL

Free kappa

6.25%

MGUS #10

67

F

0.6 g/dL

IgG kappa

5.56%

MGUS #11

56

F

NQ; IgA, 464 mg/dL

IgA kappa

6.00%